Catalent Inc. Announces Plans to Invest $175M in their Manufacturing and R&D Facilities
Catalent, Inc., a multinational corporation who partners with various pharma, biotech, and consumer health companies, has announced their plans to invest $175 million into the expansion of their R&D facility in Clark County. This expansion will bring 277 new, high-wage jobs for Kentuckians.
The company intends to expand their existing 190,000 sq ft facility by adding an additional 90,000 sqft. This will increase their manufacturing capacity within their oral dose division. The company will also acquire a nearly 17,000 sq ft facility to house their R&D operations. Work is expected to begin in 2022 and wrap up in 2027.
This new facility will create job openings for scientists, manufacturing, quality assurance, maintenance, and warehouse positions. As a leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world, Catalent is constantly engaging in R&D activities. They contribute broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply more than 70 billion doses of nearly 7,000 products to over 1,000 customers annually.
“We look forward to further investing and growing in Winchester,” said Chris Rosenbaum, general manager of Catalent in Winchester. “The state of Kentucky’s talented workforce, tight-knit community and business environment provides major advantages to the future growth of Catalent.”
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
